Based on the positive results obtained from clinical trials, the Food and Drug Administration (FDA) approved osimertinib for the treatment of patients with metastatic T790M- and EGFR-positive mutation in NSCLC (7, 10). Here, EGFR is linked to non-small cell lung carcinoma.